Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

NCT07713745 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Neurofibromatosis Type 2
Vestibular Schwannoma
Non-vestibular Schwannoma
Meningioma
Ependymoma
NF2-related Schwannomatosis
NF2

Interventions

DRUG: Selumetinib 25mg/m2
DRUG: Luvometinib
DRUG: Serplulimab

Sponsor

Beijing Tiantan Hospital